GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GSK GlaxoSmithKline PLC

Post-Mkt 10-26 17:43:57 EDT

51.10

+0.35

+0.69%

盘后51.05

-0.05-0.10%

17:29 EDT

High51.24	Low50.85	Vol3.61M
Open50.86	D1 Closing50.75	Amplitude0.76%
Mkt Cap103.36B	Tradable Cap99.13B	Total Shares2.02B
T/O184.30M	T/O Rate0.19%	Tradable Shares1.94B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"GlaxoSmithKline PLC","latestPrice":51.1,"timestamp":1793044800000,"preClose":50.75,"halted":0,"volume":3609311,"hourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":51.1,"latestTime":"17:29 EDT","volume":30989,"amount":1583536.97033,"timestamp":1793050141075,"change":-0.05,"changeRate":-0.000978,"amplitude":0.000978},"delay":0,"changeRate":0.006896551724137959,"floatShares":1939999999,"shares":2022697682,"eps":3.127128,"marketStatus":"Post-Mkt","change":0.35,"latestTime":"10-26 17:43:57 EDT","open":50.86,"high":51.235,"low":50.85,"amount":184304077.513677,"amplitude":0.007586,"askPrice":51.39,"askSize":8,"bidPrice":51.05,"bidSize":83,"shortable":3,"etf":0,"ttmEps":3.127128,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1793059200000},"marketStatusCode":4,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":50.75,"dividendRate":0.036021,"preHourTrading":{"tag":"盘前","latestPrice":50.91,"preClose":50.75,"latestTime":"09:29 EDT","volume":29279,"amount":1490706.90694,"timestamp":1793021395439,"change":0.16,"changeRate":0.003153,"amplitude":0.011626},"postHourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":51.1,"latestTime":"17:29 EDT","volume":30989,"amount":1583536.97033,"timestamp":1793050141075,"change":-0.05,"changeRate":-0.000978,"amplitude":0.000978},"volumeRatio":0.81854,"impliedVol":0.3227,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"1173557464","title":"Earning Preview: GlaxoSmithKline PLC revenue is expected to increase by 5.09% this quarter, and institutional views are bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=1173557464","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1173557464?lang=en_us&edition=fundamental","pubTime":"2026-10-21 13:49","pubTimestamp":1792561741,"startTime":"0","endTime":"0","summary":"Abstract GlaxoSmithKline PLC will report quarterly results on October 28, 2026 Pre-Mkt; the market tracks a modest top-line and EPS expansion alongside oncology catalysts and ongoing cost...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: GlaxoSmithKline PLC revenue is expected to increase by 5.09% this quarter, and institutional views are bearish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678197262","title":"GSK Licensor Reports 'Positive' Osteosarcoma Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2678197262","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678197262?lang=en_us&edition=fundamental","pubTime":"2026-10-27 00:19","pubTimestamp":1793031556,"startTime":"0","endTime":"0","summary":"GSK  licensor Hansoh Pharmaceutical reported Monday \"positive\" results from its phase 3 trial in China of risvutatug rezetecan in patients whose osteosarcoma had progressed or relapsed after at least two prior lines of systemic therapy.The company said the trial met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy.The drug candidate reduced the risk of disease progression or death by 67% compared with chemotherapy, the firm said.The Artemis-011 study was conducted by Hansoh, and GSK holds exclusive rights to develop and commercialize risvutatug outside mainland China, Hong Kong, Macau and Taiwan, it said.Price: 51.08, Change: +0.33, Percent Change: +0.65","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","GSK","GSK.UK","BK4007","BK4585","GSKH","BK4588","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678635591","title":"GSK's Rectal Cancer Drug Meets Primary Objective in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678635591","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678635591?lang=en_us&edition=fundamental","pubTime":"2026-10-26 16:38","pubTimestamp":1793003930,"startTime":"0","endTime":"0","summary":"GSK  reported that its cancer drug Jemperli met its primary objective in the phase 2 AZUR-1 clinical trial.In an exploratory analysis, 76% of 144 evaluable patients with stage II and III microsatellite instability-high mismatch repair deficient locally advanced rectal cancer achieved a complete response to Jemperli alone.The trial also showed no disease recurrences among responders after a median follow-up of more than two years.Jemperli recently received US approval for this indication, the company added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","GSK.UK","LU1829250122.USD","BK4588","BK4007","GSK","GSKH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678152372","title":"GSK Plc Expected to Post Earnings of $1.33 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2678152372","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678152372?lang=en_us&edition=fundamental","pubTime":"2026-10-26 15:03","pubTimestamp":1792998185,"startTime":"0","endTime":"0","summary":"GSK plc <GSK.N> expected to post earnings of $1.33 a share - Earnings PreviewGSK plcGSK.N,GSKis expected to  show a rise in quarterly revenue when it reports  results on October 28 for the period ending September 30 2026The Brentford Hounslow-based  company is expected to report a 0.7% increase in revenue to $11.605 billion from $11.52 billion a year ago, according to the mean estimate from 3 analysts, based on LSEG data.LSEG's mean analyst estimate for GSK plc is for earnings of $1.33 per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" 3 \"hold\" and 1 \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for GSK plc is $58.43, about 15.1% above its last closing price of $50.75This summary was machine generated October 26 at 07:03 GMT.  All figures in US dollars unless otherwise stated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nL5N46C09C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971552830.HKD","IE00BWDBJ516.SGD","LU0306806265.USD","LU0203347892.USD","LU2468319806.SGD","LU0575583348.USD","SG9999001176.USD","LU1035777561.USD","LU1645745479.HKD","LU1400636491.USD","LU1098665638.USD","LU0225771236.USD","GSK","BK4007","LU0109981661.USD","LU0161305163.EUR","BK4588","LU0557290698.USD","LU1309081286.SGD","IE00B3T34201.USD","LU0971552673.USD","LU1481600234.SGD","LU0225283273.USD","LU2089984988.USD","LU0985481810.HKD","LU0058720904.USD","LU0203345920.USD","LU1064927863.SGD","LU1400636574.HKD","LU1228905540.USD","LU1302929846.USD","LU1228905037.USD","LU1481599808.USD","LU1670756490.USD","LU1487256676.USD","LU0306807586.USD","IE0034235071.USD","GSKH","LU0211331839.USD","LU1202635105.USD","LU0987226296.USD","GSK.UK","LU0289739699.SGD","LU0225284248.USD","LU1015430645.USD","LU1046248800.SGD","LU2646069778.SGD","SG9999001176.SGD","BK4585","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678139032","title":"GSK presents updated data from phase I BEHOLD-1 trial for Mo-Rez","url":"https://stock-news.laohu8.com/highlight/detail?id=2678139032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678139032?lang=en_us&edition=fundamental","pubTime":"2026-10-26 05:30","pubTimestamp":1792963818,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan, Mo-Rez, an investigational B7-H4-targeted antibod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-presents-updated-data-from-phase-i-behold-1-trial-for-mo-rez-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-presents-updated-data-from-phase-i-behold-1-trial-for-mo-rez-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","GSKH","GSK","LU1829250122.USD","BK4585","GSK.UK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678139056","title":"GSK announces interim results from phase II AZUR-1 trial of Jemperli","url":"https://stock-news.laohu8.com/highlight/detail?id=2678139056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678139056?lang=en_us&edition=fundamental","pubTime":"2026-10-26 05:30","pubTimestamp":1792963811,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli monotherapy as a standalone treatment approach in a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-interim-results-from-phase-ii-azur-1-trial-of-jemperli-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-interim-results-from-phase-ii-azur-1-trial-of-jemperli-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","BK4007","BK4585","GSKH","GSK.UK","GSK","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199175353","title":"Promising Cancer Data Expand Eli Lilly’s Growth Story","url":"https://stock-news.laohu8.com/highlight/detail?id=1199175353","media":"Bellwether Stocks Movement","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199175353?lang=en_us&edition=fundamental","pubTime":"2026-10-25 17:11","pubTimestamp":1792919493,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/4232.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/4232.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Promising Cancer Data Expand Eli Lilly’s Growth Story","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLYX","GSKH","GMAB","LLY","LLII","ELIL","ELIS","GSK","AZN","RHHBY","ABBV"],"isVideo":true,"video":{"duration":155,"video_url":"https://news-video-sg.skytigris.cn/videos/cdn/4232.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/4232.webp","audio_url":"https://static.tigerbbs.com/25ec71534081aa009fbd89a5ed729052.mp3","isAI":true},"gpt_icon":0},{"id":"1116028192","title":"A 42% Risk Reduction—and an 18% Stock Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=1116028192","media":"Bellwether Stocks Movement","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116028192?lang=en_us&edition=fundamental","pubTime":"2026-10-24 22:29","pubTimestamp":1792852174,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/4211.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/4211.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"A 42% Risk Reduction—and an 18% Stock Drop","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIS","SNY","BMY","VIR","NVO","ABBV","BNTX","BIIB","NVOC","MRNY","NVOH","NVS","VERU","GILD","NVAX","GSK","AMGN","MRK","GSKH","REGN","PFE","ELIL","AZN","NVOX","LLII","JNJ","LLY","ABT","MRNX","LLYX","MRNA"],"isVideo":true,"video":{"duration":128,"video_url":"https://news-video-sg.skytigris.cn/videos/cdn/4211.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/4211.webp","audio_url":"https://static.tigerbbs.com/a8f7391e9856508d03b13022af060b37.mp3","isAI":true},"gpt_icon":0},{"id":"1164076214","title":"GSK's New Drug Sparks Competition in Hepatitis B Functional Cure Race as Domestic Pharmaceutical Companies Vie for Billion-Yuan Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1164076214","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164076214?lang=en_us&edition=fundamental","pubTime":"2026-10-23 14:21","pubTimestamp":1792736463,"startTime":"0","endTime":"0","summary":"Recently, GlaxoSmithKline PLC (GSK) announced that its antisense oligonucleotide (ASO) drug Bepirovirsen (brand name Hibsago) received FDA approval for market launch, indicated for combination with...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","GSK","ASO","GSKH","BK4200","GSK.UK","BK4532","BK4585","BK4007","BK4561","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677967505","title":"GSK Rises Thursday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2677967505","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677967505?lang=en_us&edition=fundamental","pubTime":"2026-10-23 00:08","pubTimestamp":1792685280,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.GSK PLC  shares rose 2.46% to GBP19.14 Thursday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index  falling 0.26% to 10,725.03.GSK PLC closed 16.13% below its 52-week high of GBP22.82, which the company reached on February 18th.Trading volume totaled 4.3 million, compared to the 50-day average of 6.4 million.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GSK","LU1829250122.USD","BK4585","GSK.UK","BK4532","GSKH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677460614","title":"GlaxoSmithKline (GSK) Receives a Sell from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2677460614","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677460614?lang=en_us&edition=fundamental","pubTime":"2026-10-22 01:25","pubTimestamp":1792603537,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Zain Ebrahim maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.00. According to TipRanks, Ebrahim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-receives-a-sell-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-receives-a-sell-from-j-p-morgan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2357305700.SGD","BK4127","LU1732799900.SGD","LU0210528500.USD","LU0795875169.SGD","LU1732800096.USD","LU2264538146.SGD","LU0106831901.USD","LU1064131342.USD","BK4581","KBWB","LU1791710582.SGD","LU1791710400.SGD","LU0912757837.SGD","LU1720051108.HKD","LU0320765646.SGD","LU0795875086.SGD","BK4532","LU2111349929.HKD","GSK","LU1162221912.USD","LU0158827948.USD","LU0225283273.USD","IE00B3S45H60.SGD","LU2487616109.SGD","LU2271345857.HKD","LU0053666078.USD","LU1244550494.USD","LU1989772840.SGD","IAI","LU1074936037.SGD","LU1244550221.USD","BK4588","LU0971096721.USD","LU0106261372.USD","LU0314104364.USD","LU1363072403.SGD","BK4504","GSKH","LU1988902786.USD","LU0528227936.USD","LU2028103732.USD","LU1548497426.USD","LU0006306889.USD","LU2089284900.SGD","GSK.UK","LU1244550577.SGD","IE00BKVL7J92.USD","LU1720051017.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677672835","title":"GSK’s ViiV announce real-world evidence from OPERA cohort using Cabenuva","url":"https://stock-news.laohu8.com/highlight/detail?id=2677672835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677672835?lang=en_us&edition=fundamental","pubTime":"2026-10-21 21:20","pubTimestamp":1792588815,"startTime":"0","endTime":"0","summary":"ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced evidence from the OPERA o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsks-viiv-announce-real-world-evidence-from-opera-cohort-using-cabenuva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsks-viiv-announce-real-world-evidence-from-opera-cohort-using-cabenuva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","GSKH","BK4007","BK4532","XBI","XLV","GSK.UK","BK4588","GSK","LABU","LU1829250122.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677162951","title":"Hutchmed Closes GSK License Deal for KRAS-EGFR Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2677162951","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677162951?lang=en_us&edition=fundamental","pubTime":"2026-10-21 16:26","pubTimestamp":1792571194,"startTime":"0","endTime":"0","summary":"Hutchmed  closed a licensing agreement granting a GSK  unit worldwide development and commercialization rights to its experimental cancer drug HMPL-A830, excluding mainland China, Hong Kong, Macau and Taiwan, the company said late Tuesday.Under the deal, Hutchmed expects to receive an upfront payment of $110 million, with potential milestone payments of up to about $1.19 billion and tiered royalties on annual net sales.Hutchmed will lead global phase I development, while GSK will oversee subsequent clinical development and commercialization in its licensed territories, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4007","BK4585","LU1829250122.USD","HCM","GSK","GSK.UK","GSKH","BK4588","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167552378","title":"Movement Alert｜GlaxoSmithKline PLC Overnight Decline 3.61%, Jemperli FDA accelerated approval draws a cautious market response","url":"https://stock-news.laohu8.com/highlight/detail?id=1167552378","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167552378?lang=en_us&edition=fundamental","pubTime":"2026-10-21 15:01","pubTimestamp":1792566103,"startTime":"0","endTime":"0","summary":"On October 21, GlaxoSmithKline PLC fell 3.61% Overnight, trading at $49.93 per share, with turnover of $157,700.The clearest recent catalyst was the FDA's accelerated approval of Jemperli for some...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GSK Slips on FDA Accelerated Approval for Jemperli","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677137610","title":"GSK’s Hibsago approved by FDA for treatment of CHB","url":"https://stock-news.laohu8.com/highlight/detail?id=2677137610","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677137610?lang=en_us&edition=fundamental","pubTime":"2026-10-21 08:05","pubTimestamp":1792541113,"startTime":"0","endTime":"0","summary":"GSK (GSK) “announced that the FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B, CHB, virus infection in combination...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsks-hibsago-approved-by-fda-for-treatment-of-chb-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsks-hibsago-approved-by-fda-for-treatment-of-chb-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","BK4007","GSK","GSKH","CHB","BK4588","LABU","BK4532","GSK.UK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199030903","title":"Movement Alert｜GlaxoSmithKline PLC Intraday Rise 3.21% in Regular Trading, Jemperli Wins FDA Accelerated Approval for Some Advanced Rectal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1199030903","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199030903?lang=en_us&edition=fundamental","pubTime":"2026-10-21 03:47","pubTimestamp":1792525626,"startTime":"0","endTime":"0","summary":"On October 21, GlaxoSmithKline PLC rose 3.21% in Regular Trading, trading near $51.00, with turnover of $194 million.The main catalyst was an FDA accelerated approval for Jemperli to treat certain...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GSK Jumps on FDA Accelerated Approval for Jemperli","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154644298","title":"One Failed Endpoint Just Erased Most of EyePoint’s Value","url":"https://stock-news.laohu8.com/highlight/detail?id=1154644298","media":"Bellwether Stocks Movement","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154644298?lang=en_us&edition=fundamental","pubTime":"2026-10-20 13:23","pubTimestamp":1792473787,"startTime":"0","endTime":"0","summary":"","market":"nz","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3940.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/3940.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"One Failed Endpoint Just Erased Most of EyePoint’s Value","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOC","MRNX","LLY","JNJ","ELIL","BNTX","GSK","MRK","AZN","ELIS","EYPT","NVS","NVOH","MRNA","SNY","GSKH","PFE","VIR","MRNY","AMGN","LLII","BMY","GILD","LLYX","BIIB","NVOX","REGN","VERU","NVO","ABT","ABBV","NVAX"],"isVideo":true,"video":{"duration":88,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/3940/render_3940_1792463858979.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3940.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/3940/tts/voiceover_56281b7943d4385b1b0bfe49.mp3","isAI":true},"gpt_icon":0},{"id":"2676611653","title":"RBC Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676611653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676611653?lang=en_us&edition=fundamental","pubTime":"2026-10-20 09:46","pubTimestamp":1792460819,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Trung Huynh from RBC Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,975.00. Accordi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-glaxosmithkline-gsk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-glaxosmithkline-gsk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676633430","title":"AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2676633430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676633430?lang=en_us&edition=fundamental","pubTime":"2026-10-20 02:25","pubTimestamp":1792434320,"startTime":"0","endTime":"0","summary":"AnaptysBio (ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK (GSK) company, and Quimilza with Vand...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/anaptysbio-notes-jemperli-approved-in-u-s-for-locally-advanced-rectal-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/anaptysbio-notes-jemperli-approved-in-u-s-for-locally-advanced-rectal-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","FFTY","BK4139","BK4007","ANAB","BK4585","GSKH","GSK.UK","GSK","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676680554","title":"GSK confirms FDA approval of Jemperli for certain rectal cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2676680554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676680554?lang=en_us&edition=fundamental","pubTime":"2026-10-20 00:40","pubTimestamp":1792428014,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced the Food and Drug Administration has approved Jemperli as “the first and only immunotherapy” for adults with stage II and III m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-confirms-fda-approval-of-jemperli-for-certain-rectal-cancers-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-confirms-fda-approval-of-jemperli-for-certain-rectal-cancers-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","IEIH","IBB","GSK","GNMX","GDOC","LU1829250122.USD","BBP","SYNB","IDNA","MEDI","MRNY","BK4007","BK4588","BK4532","BMED","IYH","PINK","BK4585","FRTY","PSCH","GSKH","RSPH","LABU","TBXU","XLVX","NVIB","GSK.UK","MRNX","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.025},{"period":"1month","weight":0.0209},{"period":"3month","weight":-0.0117},{"period":"6month","weight":-0.0678},{"period":"1year","weight":0.1144},{"period":"ytd","weight":0.0349}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019112},{"month":4,"riseRate":0.659574,"avgChangeRate":0.030828},{"month":5,"riseRate":0.404255,"avgChangeRate":-0.008644},{"month":6,"riseRate":0.595745,"avgChangeRate":0.010234},{"month":7,"riseRate":0.531915,"avgChangeRate":0.003565},{"month":8,"riseRate":0.574468,"avgChangeRate":0.00509},{"month":9,"riseRate":0.510638,"avgChangeRate":0.004965},{"month":10,"riseRate":0.531915,"avgChangeRate":0.013924},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"GlaxoSmithKline PLC","nameEN":"GlaxoSmithKline PLC","securityTypeName":"DR","adrRate":"1:2"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GlaxoSmithKline PLC(GSK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GlaxoSmithKline PLC,GSK,GlaxoSmithKline PLC股票,GlaxoSmithKline PLC股票老虎,GlaxoSmithKline PLC股票老虎国际,GlaxoSmithKline PLC行情,GlaxoSmithKline PLC股票行情,GlaxoSmithKline PLC股价,GlaxoSmithKline PLC股市,GlaxoSmithKline PLC股票价格,GlaxoSmithKline PLC股票交易,GlaxoSmithKline PLC股票购买,GlaxoSmithKline PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GlaxoSmithKline PLC(GSK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GlaxoSmithKline PLC(GSK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}